Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Treating Impaired Cognition in Schizophrenia

Author(s): H. M. Ibrahim and C. A. Tamminga

Volume 13, Issue 8, 2012

Page: [1587 - 1594] Pages: 8

DOI: 10.2174/138920112800784772

Price: $65

Abstract

Cognitive impairment is a core feature of schizophrenia that substantially accounts for poor functional outcomes associated with this disease in areas such as work, independent living and social relationships. Until recently, drug development in schizophrenia has focused on developing compounds that mainly target the positive psychotic symptoms of the illness. Although current antipsychotic drugs treat psychosis in schizophrenia rather well, their impact on cognitive dysfunction is minimal. In recent years there has been growing interest in developing novel treatments for cognitive deficits in schizophrenia. In this review we discuss pharmacologic strategies considered most likely to improve cognition. These putative molecular targets include receptors for acetylcholine, dopamine, glutamate, g-aminobutyric acid (GABA), serotonin and histamine. In addition, we propose that not only pharmacological, but also psychological treatments should be considered to enhance cognition in schizophrenia.

Keywords: Cognition, Acetylcholine, Glutamate, Dopamine, Histamine, Serotonin, GABA, Cognitive remediation, core feature, schizophrenia, social relationships, schizophrenia, psychotic symptoms, pharmacologic strategies


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy